Strategic Partnerships PhotoniCare has secured a Series B funding round and partnered with Gentex, highlighting a proven path for co-development, manufacturing collaboration, and channel expansion. Leverage these relationships to position OtoSight as a complementary diagnostic platform in multi-vendor hospital supply ecosystems.

Expansion Footprint Recent move of headquarters to Grand Rapids and expanded office presence indicate growth and regional sales potential in the Midwest. Target healthcare systems in nearby states and pursue enterprise-wide contracts with regional IDNs and pediatric care networks.

Clinical Validation OtoSight is FDA-cleared with 90+% reader accuracy and extensive clinical publications, plus multiple awards. Use these credentials to accelerate conversations with decision-makers, emphasize reimbursement-ready value propositions, and support pilot programs in pediatrics and primary care pathways.

Funding Momentum Ongoing equity raises and NIH SBIR II funding demonstrate strong investor confidence and potential for continued product development. Align sales pitches with roadmap milestones, such as AI-enabled diagnostics or integration capabilities, to secure long-term procurement commitments.

Market Demand There is a large total addressable spend on ear infection management and a documented misdiagnosis gap among primary care clinicians. Position OtoSight as a high-accuracy, non-invasive solution that reduces misdiagnoses, supports better treatment decisions, and can drive cost savings for health systems.